In the realm of cancer diagnosis, the human naked eye may sometimes fall short in detecting subtle abnormalities that could be indicative of disease. However, with the remarkable advancements in artificial intelligence (AI), the chances of error can be significantly reduced, ultimately revolutionizing the accuracy and effectiveness of cancer diagnostics. Leading this transformative journey is Paige, a pioneering company at the forefront of utilizing AI to advance the field of digital pathology.
Paige leverages the power of AI and deep learning algorithms to empower pathologists and clinicians with an unparalleled level of precision in cancer diagnosis. By combining the expertise of medical professionals with state-of-the-art computational pathology solutions, Paige’s platform revolutionizes the interpretation of medical images, leaving little room for oversight. Its AI-driven technology detects even the most subtle signs of cancer, to help ensure fewer potential abnormalities are overlooked. By reducing the chance of human error, Paige is drastically improving diagnostic accuracy and equipping healthcare professionals with the tools they need to make timely and informed treatment decisions.
As one of the leading companies in the digital pathology market of 2023, Paige continues to push the boundaries of what is possible in cancer diagnosis. By harnessing the potential of AI, Paige is transforming the landscape of pathology, enabling earlier detection, personalized treatment plans, and improved patient outcomes.
In an interview with Andy Moye, the Chief Executive Officer of Paige shares the company’s unwavering commitment to leveraging AI’s potential in healthcare and revolutionizing the field of digital pathology in a new era of accurate and efficient cancer diagnosis.
Following are excerpts from the interview:
Kindly tell us the source of inspiration. What led you to venture into the field of digital pathology?
For nearly two decades, I have been an industry leader in the fields of molecular diagnostics, biotechnology, and life sciences specializing in pathology, oncology, genomics, and precision medicine. My journey in pathology began at US Labs in 2005 when digital pathology was still in its infancy stage but showing great promise. I helped develop and deliver a system that enabled pathologists to send their samples to a central lab for analysis. Then I moved to Caris Diagnostics, where I ran a lab with more advanced digital pathology capabilities and saw what digital pathology could do. When I became head of commercial operations for Philips in 2016, I saw the potential AI applications could add to digital pathology and how truly transformative it could be.
Now, as the CEO of Paige, we are dedicated to advancing digital pathology with the use of cutting-edge artificial intelligence technology for cancer detection. Our goal is to create industry-leading AI products and collaborate with labs around the world to improve access to quality patient care.
With Paige’s AI, pathologists can focus their attention on areas suspicious of cancer and see cancer on a slide they could potentially miss with the naked eye. It is a tool pathologists can use similar to a second pair of eyes to help detect every bit of cancerous tissue with confidence.
Brief us about the company and shed some light on your operations there in contributing to the company’s growth.
At Paige, we believe that better technology is the answer to better patient care. Our mission is to develop and deliver a new generation of diagnostic and biomarker AI applications, empowering pathologists and transforming oncology.
Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare, Paige is uniquely positioned to transform the field of pathology. Our access to highly specialized, diverse global data has provided Paige with one of the largest data sets used to develop AI software. This enabled us to build the first-ever FDA-approved AI pathology product, Paige Prostate Detect, as well as best-in-class detection algorithms for uncovering cancer features from H&E-stained whole slide images alone.
Can you elaborate upon the core values, mission, and vision on which the company is built?
Paige operates under the guidance of the principles of being A.D.E.P.T. This means that we are dedicated to being accountable, disruptive, execution-focused, patient-centric, and trusting. We strive to create a supportive environment for the development of innovative products for clinicians, with the ultimate goal of transforming the world of cancer care through the use of artificial intelligence.
We remind clinicians that along with techniques like IHC, PCR, NGS, and ISH, AI is another powerful tool that can help pathologists in arriving at accurate diagnoses more efficiently and confidently. Digital pathology and AI will never replace pathologists, but it certainly supports them in their assessment.
Our Paige Prostate Suite and Paige Breast Suite are examples of tools that help pathologists identify even the smallest and most complex cancers. For instance, the use of the Paige Breast Lymph Node has shown a 25 percent improvement in pathologist sensitivity1, allowing for the detection of metastatic lesions that may have been previously missed by the naked eye. This has a direct impact on patient treatment and care.
What diagnostic tools does the organization find to be essential in conducting its pathology operations?
Paige’s products include:
- The Paige Platform is a comprehensive platform that powers a lab’s complete digital pathology workflow, consisting of cloud storage, seamless access to Paige and third-party AI applications, and a secure connection to laboratory information systems (LIS) and other clinical information systems.
- FullFocus®, an FDA-cleared whole-slide image viewer that delivers advanced digital slide review tools, and FullFolio™, our AI-powered clinical worklist.
- The Paige Prostate Suite is comprised of Paige Prostate Detect, Paige Prostate Grade & Quantify, Paige Prostate Perineural Invasion, and the Paige Prostate Biomarker Suite.
- The Paige Breast Suite, including both Paige Breast Detect, Paige Breast Neoplasm, Paige Breast Mitosis, and Paige Breast Lymph Node, as well as HER2Complete™.
- Integrations with leading third-party AI including Mindpeak IHC biomarker algorithms and others on the way.
What endeavors is the organization currently pursuing to improve its pathology measures for patients?
Paige is actively collaborating with numerous organizations in the medical and pathology industries, forming strong partnerships with esteemed institutions and teaching hospitals such as Oxford and the University Medical Center in Utrecht.
Additionally, we partner with Quest Diagnostics to enhance their capabilities and simplify the interface between their technologies to benefit pathologists.
Paige has also established technology partnerships with Microsoft and Leica Biosystems, while also partnering with other companies worldwide to enhance digital pathology. The ultimate goal of these collaborations is to drive a new era of diagnostics and precision treatment that can significantly improve the lives of patients through digital pathology and AI.
How do you envision scaling your organization’s services and operations in 2023 and beyond?
Paige aims to provide an impressive portfolio of AI applications to pathologists. We are creating new applications for breakthrough cancer treatment, including for sub-specialties, over the next few months.
What are some of the testimonials or recognition that accurately highlight your organization’s position in the market?
Our partnership with Paige brings us a big step closer to our shared goal of making the pathological diagnosis of breast cancer quicker, more accurate and more reproducible. I am extremely excited that we will combine our respective strengths in analyzing H&E and IHC-stained tissue samples to make the vision of utilizing AI within pathology a reality.
Based on an investigational clinical study involving 3 pathologists and data from 148 patients.
In the United States, FullFocus® (K201005) and Paige Prostate Detect (DEN200080) are cleared for clinical use with Philips Ultrafast Scanner and for use with H&E-stained slides only. All other Paige Prostate and Paige Breast Suite applications and use cases are limited to Research Use Only and not for use in diagnostic procedures.
